Source Report
Research Question
Conduct a detailed competitive analysis comparing Tempus AI to Foundation Medicine (Roche), Guardant Health (GH), Flatiron Health (Roche), and Illumina across dimensions including: dataset scale and multimodality, reimbursement status of flagship assays, pharma partnership deal volume and publicly disclosed values, clinical workflow integration, and AI/ML capabilities. Identify where Tempus has differentiated advantages and where rivals have structural advantages. Produce a comparison table across key dimensions.
Dataset Scale and Multimodality
Tempus AI leverages its proprietary OS platform to aggregate multimodal data from over 5,000 U.S. healthcare sites via 700+ connections, creating a de-identified library exceeding 450 petabytes that links real-time clinical EHR notes (1.6B+ pages), genomics (4M+ sequenced samples), imaging (8M+ records), and transcriptomics (350K+ profiles) for 8.5M+ research records—90x larger than TCGA—enabling AI models to predict outcomes like immunotherapy response via signatures like Immune Profile Score (IPS), which outperforms PD-L1 alone by integrating histopathology and genomics.[1][2]
- 45M+ total patient records; 55% U.S. oncologist reach; 65% academic centers; used in 1,500+ research projects[2]
- Powers Tempus Lens for cohort building/matching; agentic AI extracts unstructured text into structured data for longitudinal tracking[3]
Implications for Competitors: Tempus' near-real-time, EHR-linked multimodality creates a "living" dataset for dynamic AI training, unlike static snapshots from rivals.
Competition Barriers: New entrants need 5-10 years and $500M+ to match scale; pharma must integrate Tempus' data moat or risk suboptimal models.
Reimbursement Status of Flagship Assays
Tempus' xT CDx (648-gene solid tumor NGS) gained FDA approval and CMS ADLT status at $4,500 (vs. LDT ~$2,900), with Q4 2025 oncology ASP $1,640 (rising to >$2,200 via xF liquid biopsy PMA submission and xR RNA); xF1 (liquid) pending full NCD 90.2 coverage; Medicare covers qualifying advanced solid tumors, driving 26% oncology volume growth.[2]
- Commercial in-network with Cigna/Humana/BCBS; hereditary ASP ~$800[2]
| Company | Flagship Assay | FDA Status | Medicare Reimbursement (2025/26) | ASP/Notes |
|---|---|---|---|---|
| Tempus AI | xT CDx (solid), xF (liquid) | Approved (xT); xF PMA submitted | ADLT $4,500 (xT); pending NCD 90.2 (xF) | $1,640 oncology; rising >$2,200[2] |
| Foundation Medicine (Roche) | FoundationOne CDx | Approved (broad CDx) | NCD all solid tumors; no OOP for qualifying Medicare | Mature coverage; 100+ CDx indications[4] |
| Guardant Health | Guardant360 CDx (liquid), Reveal (MRD) | Approved | 360 CDx covered; Reveal CRC surveillance $1,640; chemo monitoring submitted MolDX | Oncology ASP ~$3,000[5] |
| Flatiron Health (Roche) | N/A (data platform) | Data/RWE | No assays | Supports CGP reimbursement evidence[6] |
| Illumina | TruSight Oncology Comprehensive | Approved | CLFS $2,989 (PLA 0543U) eff. 2026 | Enables lab-run CGP[7] |
Implications: Rivals like Foundation/Guardant hold mature pan-tumor NCDs; Tempus catching up via CDx migration (30% xT vol.).
Competition Barriers: FDA/CMS pathways demand clinical utility data; Tempus' volume accelerates parity by 2026.
Pharma Partnership Deal Volume and Values
Tempus signed 70+ data deals in 2025 with 19/20 top pharma (AstraZeneca/Pathos foundation model; Merck AI; Pfizer/GSK/BMS/Novartis), yielding >$1.1B TCV (126% NRR), $316M data rev (31% growth)—monetizing multimodal RWE for trial design/biomarkers via Lens AI.[2][8]
- 250+ biotechs; $2B+ contracts signed[2]
Implications: Tempus leads new deal velocity via AI-accessible data; Roche's legacy acquisitions (Foundation $2.4B '18, Flatiron $1.9B '18) provide internal moats but less external revenue.[9][10]
Competition Barriers: Guardant ($210M biopharma rev, Merck collab)[5]; Flatiron internal; Illumina alliances (AstraZeneca/Merck/Lilly Billion Cell Atlas)[11]; scale needs proprietary data+AI.
Clinical Workflow Integration
Tempus One (GenAI assistant) embeds in EHRs (e.g., Epic/Flatiron OncoEMR), querying patient data/guidelines (ASCO-integrated), auto-matching trials (TIME screened 245K pts), surfacing care gaps (NEXT)—reducing admin via agentic workflows across 5K sites/55% oncologists.[12][2]
- Orders/results flow bidirectionally; 123K+ Algos ordered[2]
Implications: Tempus' OS turns EHRs into AI hubs, unlike assay-focused rivals.
Competition Barriers: Flatiron OncoEMR leads EHR but lacks Tempus' genomic depth; Guardant/Foundation diagnostics integrate less seamlessly.
AI/ML Capabilities
Tempus' agentic AI platform (Tempus One/Lens) fine-tunes foundation models on proprietary 450PB multimodal data for IPS (immunotherapy), PurIST (PDAC subtyping), ECG-AFib (FDA-cleared), pathology viability prediction—powering 60+ algos, trial matching, outcome forecasting.[2]
- Collaborations: AstraZeneca/Pathos largest oncology foundation model[2]
Implications: Tempus' data moat yields superior models (e.g., IPS > PD-L1); Guardant/Illumina focus ML on assays; Roche/Flatiron lag agentic scale.
| Dimension | Tempus Advantage | Rival Structural Edge |
|---|---|---|
| Data Scale | Massive multimodal (8.5M recs) | Flatiron (5M EHR); FMI CGDB (100K CG) |
| Reimbursement | Improving ($1.6K→$2.2K) | FMI/Guardant mature NCD/CDx |
| Pharma Deals | 70+/$1.1B TCV | Roche acquisitions ($4B+ total); Guardant $210M rev |
| Workflow | EHR AI (Tempus One) | Flatiron OncoEMR |
| AI/ML | Agentic foundation models | Illumina DRAGEN; Guardant epigenomics ML |
Competition Barriers: Tempus wins on data+AI flywheel; rivals lead reimbursement/integration—new entrants face insurmountable scale.
Recent Findings Supplement (March 2026)
Dataset Scale and Multimodality
Tempus AI solidified its data moat in late 2025 by announcing a record Total Remaining Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025, driven by 70+ new data licensing deals with pharma giants like AstraZeneca, Pfizer, GSK, and Merck; this TCV assumes full exercise of options and reflects committed future revenue from its multimodal library (>45M patient records, >8M imaging records, >4M sequenced samples, >350K DNA+RNA profiles), enabling AI training that outpaces rivals' siloed datasets.[1][2][3]
- Tempus ended 2025 with 126% net revenue retention in data licensing, signaling sticky pharma demand for its de-identified clinical+molecular+imaging data.
- Flatiron Health (Roche) launched AI-powered global prostate cancer datasets (Feb 2026) and 6 hematology datasets (Oct 2025) with 505K patients, plus ConcertAI integration for ~500K linked patients (Jan 2026), emphasizing clinical RWD over Tempus' genomics depth.[4][5]
- Guardant launched Single Namespace Group (Nov 2025) for exabyte-scale genomic data interoperability with NetApp, IBM, Genentech; no specific size update.[6]
Implications for Competitors: Tempus' TCV provides revenue visibility into 2026+ (~$350M committed for 2026), but rivals like Flatiron leverage Roche's ecosystem for clinical depth; new entrants need pharma tie-ups to match Tempus' scale, while Guardant/Illumina focus on tools enables lab decentralization.
Reimbursement Status of Flagship Assays
Illumina secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive (TSO Comprehensive) at $2,989.55/test effective Jan 1, 2026 (PLA code 0543U), unlocking Medicare access for comprehensive genomic profiling (CGP) in advanced cancer and enabling in-house lab adoption beyond centralized testing.[7][8]
- Tempus received FDA 510(k) for Tempus xR IVD RNA NGS assay (Sep 2025); plans xF liquid biopsy FDA submission Q4 2025 and xR PMA; no new reimbursement noted.[9][10]
- Guardant360 CDx gained FDA CDx approval for BRAF V600E mCRC with Pfizer's Braftovi (Jan 2026); Shield blood test added to NCCN guidelines, with Medicare/TRICARE coverage.[11][12]
- Foundation Medicine hit 100 CDx indications (Dec 2025; 57 US, 43 Japan); no new reimbursement specifics.[13]
Implications for Competitors: Illumina's reimbursement structurally advantages decentralized CGP (e.g., community labs), pressuring Tempus/Guardant/FMI centralized models; Tempus must prioritize FDA/CMS for xF/xR to compete, as Guardant/FMI lead in CDx breadth.
| Company | Flagship Assay(s) | Recent Reimbursement/FDA (Post-9/9/25) | Medicare Rate |
|---|---|---|---|
| Tempus AI | xR IVD (RNA NGS), xT CDx | FDA 510(k) xR (Sep 2025); xF submission Q4 2025 | None new |
| Foundation Medicine (Roche) | FoundationOne CDx/Liquid CDx | 100 CDx indications (Dec 2025) | Established CGP |
| Guardant Health | Guardant360 CDx, Shield | CDx for BRAF mCRC (Jan 2026); Shield NCCN | Shield covered |
| Flatiron Health (Roche) | N/A (RWD platform) | N/A | N/A |
| Illumina | TruSight Oncology Comprehensive | CMS $2,989.55 (Jan 2026) | $2,989.55 |
Pharma Partnership Deal Volume and Values
Tempus expanded Merck multi-year deal (Mar 3, 2026) for AI biomarker discovery using de-identified multimodal data/Lens platform, building on prior ties; part of 70+ 2025 deals contributing to >$1.1B TCV (no per-deal values disclosed).[14][15]
- Guardant inked multi-year Merck deal (Jan 2026) for CDx development using Infinity platform; acquired MetaSight for up to $150M (Feb 2026) for early detection.[16][17]
- Foundation/Flatiron: Manifold AI partnership (Oct 2025) for FoundationInsights; ConcertAI data integration (Jan 2026).
- No new high-value deals for Illumina/Flatiron.
Implications for Competitors: Tempus leads volume (70+ deals, $1.1B TCV), differentiating via AI-multimodal access; Guardant matches on Merck but focuses CDx; Roche entities gain from integrations, but Tempus' TCV signals higher monetization—rivals need AI-data combos to compete.
Clinical Workflow Integration
Tempus integrated Median's FDA-cleared eyonis LCS AI lung screening into Pixel platform (Feb 2026), targeting 14.5M eligible US patients with existing reimbursement pathway ($601-700); launched Paige Predict AI pathology (Jan 2026) for 123 biomarkers/16 cancers from H&E slides.[18][19]
- Guardant/Quest multi-year deal for Shield CRC screening via Quest network (Q1 2026 rollout); Trial Library AI for trial matching (Dec 2025).[20]
- Flatiron sold clinical research business to Paradigm (Dec 2025) for OncoEMR integration.
Implications for Competitors: Tempus' Pixel/Paige embeds AI into radiology/pathology workflows, a moat vs. Guardant's screening focus; entrants must partner for EMR/radiology hooks, as Roche/Illumina lag in end-to-end integration.
AI/ML Capabilities
Tempus launched HRD-RNA algorithm (Feb 2026) for ovarian/HRD detection and Paige Predict (Jan 2026; >200K patient foundation model); Merck deal leverages GPU-powered Lens for AI training.[21]
- Flatiron debuted LLM-powered global datasets (prostate Feb 2026, hematology Oct 2025).
- Guardant/Zephyr AI for drug response predictions (Oct 2025); Single Namespace for AI data (Nov 2025).
- Foundation/Manifold AI for FoundationInsights (Oct 2025).
Implications for Competitors: Tempus differentiates with agentic AI on massive multimodal data (e.g., HRD-RNA auto-prediction), but Guardant/Flatiron close gap in RWD-AI; Illumina's multiomics (spatial/proteomics Feb 2026) enables tools play—competitors without proprietary data risk commoditization.[22]
Tempus Advantages: Unmatched TCV/deal volume, multimodal AI (Paige/HRD), workflow (Pixel).
Rivals' Structural Edges: Roche (FMI+Flatiron CDx/RWD scale), Guardant (liquid biopsy CDx leadership), Illumina (decentralized reimbursement/tools). Tempus must convert TCV to profitability (2026 EBITDA $65M guide) amid lawsuits (Guardant patents, data privacy). Confidence: High on announcements (primary sources); medium on dataset comparisons (no direct benchmarks). Additional 10-Ks strengthen quant rigor.